Recent early clinical drug development for acute kidney injury

References

• Bedford M, Stevens PE, Wheeler TW, et al. What is the real impact of acute kidney injury? BMC Nephrol. 2014;15:95.
   PubMed Web of Science ®Google Scholar
• Linder A, Fjell C, Levin A, et al. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014;189(9):1075–1081.
   PubMed Web of Science ®Google Scholar
• Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects. Crit Care. 2016;20(1):188 .
   PubMed Web of Science ®Google Scholar
• Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012;82(5):516–524.
   PubMed Web of Science ®Google Scholar
• Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med. 2015;373(15):1397–1407.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med. 2015;373(15):1408–1417.
   PubMed Web of Science ®Google Scholar
• Zarbock A, Schmidt C, Van Aken H, et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA. 2015;313(21):2133–2141.
   PubMed Web of Science ®Google Scholar
• Weisbord SD, Palevsky PM. Design of clinical trials in acute kidney injury: lessons from the past and future directions. Semin Nephrol. 2016;36(1):42–52.
   PubMed Web of Science ®Google Scholar
• Ramos AM, Gonzalez-Guerrero C, Sanz A, et al. Designing drugs that combat kidney damage. Expert Opin Drug Discov. 2015;10(5):541–556.
   PubMed Web of Science ®Google Scholar
• Sanz AB, Sanchez-Nino MD, Martin-Cleary C, et al. Progress in the development of animal models of acute kidney injury and its impact on drug discovery. Expert Opin Drug Discov. 2013;8(7):879–895.
   PubMed Web of Science ®Google Scholar
• Cruz DN, Mehta RL. Acute kidney injury in 2013: breaking barriers for biomarkers in AKI--progress at last. Nat Rev Nephrol. 2014;10(2):74–76.
   PubMed Web of Science ®Google Scholar
• Peddi V, Ratner L, Cooper M, et al. Abstract #2967 Treatment with QPI-1002, a Short Interfering (SI) RNA for the prophylaxis of delayed graft function. World transplant congress. Am J Transplant. 2014;14(S3):152–155.
   Google Scholar
• Wire B. Thrasos announces promising results for phase 2 THR-184 dose ranging clinical study for the prevention of acute kidney injury (AKI) [webpage]. 2016. [cited 2016 May 07]. Available from: http://www.businesswire.com/news/home/20160229005651/en/Thrasos-Announces-Promising-Results-Phase-2-THR-184
   Google Scholar
• Bromberg J, Weir M, Gaber A., et al. BB-3 a hepatocyte growth factor like molecule, improves outcome in kidney transplant recipients with delayed graft function. American society of nephrology kidney week 2015; San Diego. J Am Soc Nephrol. 2015;852A. abstr no TH-OR101.
   Google Scholar
• Thomas RA, Czopek A, Bellamy CO, et al. Hemin preconditioning upregulates heme oxygenase-1 in deceased donor renal transplant recipients: a randomized, controlled, phase IIB trial. Transplantation. 2016;100(1):176–183 .
   PubMed Web of Science ®Google Scholar
• Madhav Swaminathan DM, Chertow GM, Warnock DG, et al. ACT-AKI: a phase 2 multicenter, randomized, double-blind, placebo-controlled trial of AC607 for the treatment of acute kidney injury in cardiac surgery subjects kidney week 2014; November 2014; Philadelphia. J Am Soc Nephrol. 2014. abstr no HI-OR09.
   Google Scholar
• McCullough PA, Bennett-Guerrero E, Chawla LS, et al. ABT-719 for the prevention of acute kidney injury in patients undergoing high-risk cardiac surgery: a randomized phase 2b clinical trial. J Am Heart Assoc. 2016;5(8):e003549.
   PubMed Web of Science ®Google Scholar
• Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care. 2012;16(1):R14.
   PubMed Web of Science ®Google Scholar
• Bulger EM, Maier RV, Sperry J, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surgery. 2014;149(6):528–536.
   PubMed Web of Science ®Google Scholar
• AtoxBio. Clinical data: study ATB-201: recovery from AKI in subset of patients with AKI during first 7 days [webpage]. [cited 2016 Aug 12]. Available from: http://www.atoxbio.com/clinical-data-7/
   Google Scholar
• Vaseva AV, Marchenko ND, Ji K, et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012;149(7):1536–1548.
   PubMed Web of Science ®Google Scholar
• Thompson JD, Kornbrust DJ, Foy JW, et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther. 2012;22(4):255–264.
   PubMed Web of Science ®Google Scholar
• Ying Y, Kim J, Westphal SN, et al. Targeted deletion of p53 in the proximal tubule prevents ischemic renal injury. J Am Soc Nephrol. 2014;25(12):2707–2716. .
   PubMed Web of Science ®Google Scholar
• Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol. 2009;20(8):1754–1764. .
   PubMed Web of Science ®Google Scholar
• Bramlage CP, Tampe B, Koziolek M, et al. Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis. BMC Nephrol. 2010;11:31.
   PubMed Web of Science ®Google Scholar
• Hanai J. [BMP in the kidney: signaling, function and pathophysiological significance]. Clin Calcium. 2007;17(5):704–710.
   PubMedGoogle Scholar
• Leeuwis JW, Nguyen TQ, Chuva de Sousa Lopes SM, et al. Direct visualization of Smad1/5/8-mediated transcriptional activity identifies podocytes and collecting ducts as major targets of BMP signalling in healthy and diseased kidneys. J Pathol. 2011;224(1):121–132.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Zhang J, et al. Protective effect of BMP-7 against aristolochic acid-induced renal tubular epithelial cell injury. Toxicol Lett. 2010;198(3):348–357.
   PubMed Web of Science ®Google Scholar
• Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16(3):251–263.
   PubMed Web of Science ®Google Scholar
• Simic P, Vukicevic S. Bone morphogenetic proteins in development and homeostasis of kidney. Cytokine Growth Factor Rev. 2005;16(3):299–308.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem. 2005;280(9):8094–8100.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol. 2008;23(9):1395–1398.
   PubMed Web of Science ®Google Scholar
• Gould SE, Day M, Jones SS, et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int. 2002;61(1):51–60.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18(3):396–404 .
   PubMed Web of Science ®Google Scholar
• Wetzel P, Haag J, Câmpean V, et al. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int. 2006;70(4):717–723.
   PubMed Web of Science ®Google Scholar
• Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens. 2002;11(1):23–30.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tolbert EM, Lin L, et al. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int. 1999;55(2):442–453.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun AM, Dworkin LD. Hepatocyte growth factor protects renal epithelial cells from apoptotic cell death. Biochem Biophys Res Commun. 1998;246(3):821–826.
   PubMed Web of Science ®Google Scholar
• Franquesa M, Riera M, Herrero-Fresneda I, et al. Tubular epithelial cells transfected with hHGF counteracts monocyte chemotactic protein-1 up-regulation after hypoxia/reoxygenation insult. Transplant Proc. 2009;41(6):2069–2072.
   PubMed Web of Science ®Google Scholar
• Adachi E, Hirose-Sugiura T, Kato Y, et al. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury. Pharmacology. 2014;94(3–4):190–197.
   PubMed Web of Science ®Google Scholar
• Dai C, Yang J, Liu Y. Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. J Am Soc Nephrol. 2002;13(2):411–422.
   PubMed Web of Science ®Google Scholar
• Homsi E, Janino P, Amano M, et al. Endogenous hepatocyte growth factor attenuates inflammatory response in glycerol-induced acute kidney injury. Am J Nephrol. 2009;29(4):283–291.
   PubMed Web of Science ®Google Scholar
• Yamasaki N, Nagano T, Mori-Kudo I, et al. Hepatocyte growth factor protects functional and histological disorders of HgCl(2)-induced acute renal failure mice. Nephron. 2002;90(2):195–205.
   PubMed Web of Science ®Google Scholar
• Zhou D, Tan RJ, Lin L, et al. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int. 2013;84(3):509–520 .
   PubMed Web of Science ®Google Scholar
• Narayan P, Duan B, Jiang K, et al. Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol. 2016;311(2):F352–61. .
   PubMed Web of Science ®Google Scholar
• Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease. J Am Soc Nephrol. 2007;18(2):414–420.
   PubMed Web of Science ®Google Scholar
• Shiraishi F, Curtis LM, Truong L, et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol. 2000;278(5):F726–36.
   PubMed Web of Science ®Google Scholar
• Tracz MJ, Juncos JP, Croatt AJ, et al. Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney Int. 2007;72(9):1073–1080.
   PubMed Web of Science ®Google Scholar
• Tracz MJ, Juncos JP, Grande JP, et al. Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol. 2007;170(6):1820–1830.
   PubMed Web of Science ®Google Scholar
• Blydt-Hansen TD, Katori M, Lassman C, et al. Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14(3):745–754.
   PubMed Web of Science ®Google Scholar
• Karch J, Kanisicak O, Brody MJ, et al. Necroptosis interfaces with MOMP and the MPTP in mediating cell death. PLoS One. 2015;10(6):e0130520.
   PubMed Web of Science ®Google Scholar
• Xu Y, Huang S, Liu Z-G, et al. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J Biol Chem. 2006;281(13):8788–8795.
   PubMed Web of Science ®Google Scholar
• Linkermann A, Brasen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110(29):12024–12029.
   PubMed Web of Science ®Google Scholar
• Ying Y, Padanilam BJ. Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis? Cell Mol Life Sci. 2016;73(11–12):2309–2324.
   PubMed Web of Science ®Google Scholar
• Umbro I, Gentile G, Tinti F, et al. Recent advances in pathophysiology and biomarkers of sepsis-induced acute kidney injury. J Infect. 2016;72(2):131–142.
   PubMed Web of Science ®Google Scholar
• Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock (Augusta, Ga). 2002;18(6):561–566.
   PubMed Web of Science ®Google Scholar
• Peters E, Geraci S, Heemskerk S, et al. Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate. Br J Pharmacol. 2015;172(20):4932–4945.
   PubMed Web of Science ®Google Scholar
• Bauerle JD, Grenz A, Kim JH, et al. Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol. 2011;22(1):14–20.
   PubMed Web of Science ®Google Scholar
• Kaempfer R, Arad G, Levy R, et al. CD28: direct and critical receptor for superantigen toxins. Toxins. 2013;5(9):1531–1542.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Kaempfer R, Chung CS, et al. CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis. J Infect Dis. 2015;211(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328–2335.
   PubMed Web of Science ®Google Scholar
• Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376–388.
   PubMed Web of Science ®Google Scholar
• Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290(6):F1453–62.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581–590.
   PubMed Web of Science ®Google Scholar
• Shi WY, Li S, Collins N, et al. Peri-operative levosimendan in patients undergoing cardiac surgery: an overview of the evidence. Heart Lung Circ. 2015;24(7):667–672.
   PubMed Web of Science ®Google Scholar
• Niu ZZ, Wu SM, Sun WY, et al. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis. J Cardiovasc Pharmacol. 2014;63(2):107–112 .
   PubMed Web of Science ®Google Scholar
• Belletti A, Benedetto U, Biondi-Zoccai G, et al. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care. 2016;37:91–98.
   PubMed Web of Science ®Google Scholar
• Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31(5):638–644.
   PubMed Web of Science ®Google Scholar
• Orme RM, Perkins GD, McAuley DF, et al. An efficacy and mechanism evaluation study of levosimendan for the prevention of acute oRgan dysfunction in sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials. 2014;15:199.
   PubMed Web of Science ®Google Scholar
• Humphreys BD, Bonventre JV. Mesenchymal stem cells in acute kidney injury. Annu Rev Med. 2008;59(1):311–325.
   PubMed Web of Science ®Google Scholar
• Kunter U, Rong S, Boor P, et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol. 2007;18(6):1754–1764.
   PubMed Web of Science ®Google Scholar
• Tögel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Ren Physiol. 2005;289(1):F31–F42 .
   PubMed Web of Science ®Google Scholar
• Bersenev A Cell therapy clinical trial failures in 2014 [webpage]. Cells trials: current trends in cell therapy. 2015. [cited 2016 May 15]. Available from: http://celltrials.info/2015/01/04/failures-2014/
   Google Scholar
• Star RA, Rajora N, Huang J, et al. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci USA. 1995;92(17):8016–8020.
   PubMed Web of Science ®Google Scholar
• Chiao H, Kohda Y, McLeroy P, et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99(6):1165–1172.
   PubMed Web of Science ®Google Scholar
• Doi K, Hu X, Yuen PST, et al. AP214, an analogue of α-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int. 2008;73(11):1266–1274.
   PubMed Web of Science ®Google Scholar
• Simmons MN, Subramanian V, Crouzet S, et al. Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model. J Urol. 2010;183(4):1625–1629.
   PubMed Web of Science ®Google Scholar
• Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15(2):135–147.
   PubMed Web of Science ®Google Scholar
• Linkermann A. Nonapoptotic cell death in acute kidney injury and transplantation. Kidney Int. 2016;89(1):46–57 .
   PubMed Web of Science ®Google Scholar
• Kim J, Padanilam BJ. Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Ren Physiol. 2011;301(2):F450–F9.
   PubMed Web of Science ®Google Scholar
• Linkermann A, Brasen JH, Himmerkus N, et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int. 2012;81(8):751–761.
   PubMed Web of Science ®Google Scholar
• Lau A, Wang S, Jiang J, et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. Am J Transplant. 2013;13(11):2805–2818.
   PubMed Web of Science ®Google Scholar
• Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA. 2014;111(47):16836–16841.
   PubMed Web of Science ®Google Scholar
• Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Desai J, Kumar SV, et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat Commun. 2016;7:10274.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Linkermann A, Anders HJ. Necroinflammation in kidney disease. J Am Soc Nephrol. 2016;27(1):27–39.
   PubMed Web of Science ®Google Scholar
• Shutinoski B, Alturki NA, Rijal D, et al. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ. 2016;23:1628–1637.
   PubMed Web of Science ®Google Scholar
• Najjar M, Saleh D, Zelic M, et al. RIPK1 and RIPK3 kinases promote cell-death-independent inflammation by toll-like receptor 4. Immunity. 2016;45(1):46–59.
   PubMed Web of Science ®Google Scholar
• Birch RE, Schwiebert EM, Peppiatt-Wildman CM, et al. Emerging key roles for P2X receptors in the kidney. Front Physiol. 2013;4:262.
   PubMed Web of Science ®Google Scholar
• Yan Y, Bai J, Zhou X, et al. P2X7 receptor inhibition protects against ischemic acute kidney injury in mice. Am J Physiol Cell Physiol. 2015;308(6):C463–72.
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V, Legendre CM. The emerging role of complement inhibitors in transplantation. Kidney Int. 2015;88(5):967–973.
   PubMed Web of Science ®Google Scholar
• Patel H, Smith RAG, Sacks SH, et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol. 2006;17(4):1102–1111.
   PubMed Web of Science ®Google Scholar
• Leaf DE, Waikar SS. End points for clinical trials in acute kidney injury. Am J Kidney Dis. 2016. doi:10.1053/j.ajkd.2016.05.033. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• de Caestecker M, Humphreys BD, Liu KD, et al. Bridging translation by improving preclinical study design in AKI. J Am Soc Nephrol. 2015;26(12):2905–2916.
   PubMed Web of Science ®Google Scholar